Annual Accounts Payable
$14.71 M
-$23.44 M-61.44%
December 31, 2024
Summary
- As of February 25, 2025, CRSP annual accounts payable is $14.71 million, with the most recent change of -$23.44 million (-61.44%) on December 31, 2024.
- During the last 3 years, CRSP annual accounts payable has fallen by -$107.00 thousand (-0.72%).
- CRSP annual accounts payable is now -61.44% below its all-time high of $38.15 million, reached on December 31, 2023.
Performance
CRSP Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$14.71 M
-$869.00 K-5.58%
December 31, 2024
Summary
- As of February 25, 2025, CRSP quarterly accounts payable is $14.71 million, with the most recent change of -$869.00 thousand (-5.58%) on December 31, 2024.
- Over the past year, CRSP quarterly accounts payable has increased by +$5.26 million (+55.62%).
- CRSP quarterly accounts payable is now -67.42% below its all-time high of $45.15 million, reached on March 31, 2023.
Performance
CRSP Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
CRSP Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -61.4% | +55.6% |
| 3 y3 years | -0.7% | +55.6% |
| 5 y5 years | +147.5% | +55.6% |
CRSP Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -61.4% | at low | -67.4% | +55.6% |
| 5 y | 5-year | -61.4% | +147.5% | -67.4% | +147.5% |
| alltime | all time | -61.4% | +6871.1% | -67.4% | +828.6% |
CRISPR Therapeutics AG Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $14.71 M(-61.4%) | $14.71 M(-5.6%) |
| Sep 2024 | - | $15.58 M(+64.8%) |
| Jun 2024 | - | $9.45 M(-42.6%) |
| Mar 2024 | - | $16.46 M(-56.8%) |
| Dec 2023 | $38.15 M(+39.1%) | $38.15 M(+45.9%) |
| Sep 2023 | - | $26.15 M(-5.2%) |
| Jun 2023 | - | $27.59 M(-38.9%) |
| Mar 2023 | - | $45.15 M(+64.6%) |
| Dec 2022 | $27.43 M(+85.1%) | $27.43 M(-14.6%) |
| Sep 2022 | - | $32.11 M(+27.2%) |
| Jun 2022 | - | $25.24 M(-6.9%) |
| Mar 2022 | - | $27.11 M(+83.0%) |
| Dec 2021 | $14.82 M(+62.9%) | $14.82 M(+45.7%) |
| Sep 2021 | - | $10.17 M(+0.2%) |
| Jun 2021 | - | $10.14 M(-22.4%) |
| Mar 2021 | - | $13.07 M(+43.7%) |
| Dec 2020 | $9.09 M | $9.09 M(-52.2%) |
| Sep 2020 | - | $19.02 M(+43.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2020 | - | $13.22 M(+17.2%) |
| Mar 2020 | - | $11.28 M(+89.7%) |
| Dec 2019 | $5.94 M(+17.3%) | $5.94 M(+76.2%) |
| Sep 2019 | - | $3.37 M(-52.8%) |
| Jun 2019 | - | $7.14 M(+0.2%) |
| Mar 2019 | - | $7.13 M(+40.7%) |
| Dec 2018 | $5.07 M(+209.3%) | $5.07 M(-2.9%) |
| Sep 2018 | - | $5.22 M(+16.6%) |
| Jun 2018 | - | $4.48 M(+75.9%) |
| Mar 2018 | - | $2.55 M(+55.3%) |
| Dec 2017 | $1.64 M(-64.1%) | $1.64 M(-22.5%) |
| Sep 2017 | - | $2.12 M(-17.3%) |
| Jun 2017 | - | $2.56 M(-35.0%) |
| Mar 2017 | - | $3.94 M(-13.8%) |
| Dec 2016 | $4.57 M(+188.4%) | $4.57 M(+135.2%) |
| Sep 2016 | - | $1.94 M(-47.3%) |
| Jun 2016 | - | $3.69 M(+132.8%) |
| Dec 2015 | $1.58 M(+650.7%) | $1.58 M |
| Dec 2014 | $211.00 K | - |
FAQ
- What is CRISPR Therapeutics AG annual accounts payable?
- What is the all time high annual accounts payable for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG annual accounts payable year-on-year change?
- What is CRISPR Therapeutics AG quarterly accounts payable?
- What is the all time high quarterly accounts payable for CRISPR Therapeutics AG?
- What is CRISPR Therapeutics AG quarterly accounts payable year-on-year change?
What is CRISPR Therapeutics AG annual accounts payable?
The current annual accounts payable of CRSP is $14.71 M
What is the all time high annual accounts payable for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high annual accounts payable is $38.15 M
What is CRISPR Therapeutics AG annual accounts payable year-on-year change?
Over the past year, CRSP annual accounts payable has changed by -$23.44 M (-61.44%)
What is CRISPR Therapeutics AG quarterly accounts payable?
The current quarterly accounts payable of CRSP is $14.71 M
What is the all time high quarterly accounts payable for CRISPR Therapeutics AG?
CRISPR Therapeutics AG all-time high quarterly accounts payable is $45.15 M
What is CRISPR Therapeutics AG quarterly accounts payable year-on-year change?
Over the past year, CRSP quarterly accounts payable has changed by +$5.26 M (+55.62%)